Jingrong Tang

1 month ago | biorxiv.org | Olivia White |Zahra Aligabi |Kendall H. Burks |Jingrong Tang

AbstractCurrent lipid-lowering drugs are relatively ineffective in reducing low-density lipoprotein (LDL) cholesterol in patients with Familial Hypercholesterolemia (FH) due to a dysfunctional LDL receptor (LDLR). However, LDL cholesterol reductions have been achieved in FH patients using angiopoietin-like 3 (ANGPTL3) inhibitors, which act through an uncharacterized, LDLR-independent pathway that requires endothelial lipase (EL).